Logo image of CURI

CURIOSITYSTREAM INC (CURI) Stock Fundamental Analysis

NASDAQ:CURI - Nasdaq - US23130Q1076 - Common Stock - Currency: USD

6.66  +0.12 (+1.83%)

Premarket: 6.84 +0.18 (+2.7%)

Fundamental Rating

4

Overall CURI gets a fundamental rating of 4 out of 10. We evaluated CURI against 71 industry peers in the Entertainment industry. While CURI has a great health rating, there are worries on its profitability. CURI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CURI had negative earnings in the past year.
CURI had a positive operating cash flow in the past year.
In the past 5 years CURI always reported negative net income.
CURI had negative operating cash flow in 4 of the past 5 years.
CURI Yearly Net Income VS EBIT VS OCF VS FCFCURI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CURI has a Return On Assets of -15.02%. This is in the lower half of the industry: CURI underperforms 73.24% of its industry peers.
CURI's Return On Equity of -22.37% is in line compared to the rest of the industry. CURI outperforms 46.48% of its industry peers.
Industry RankSector Rank
ROA -15.02%
ROE -22.37%
ROIC N/A
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
CURI Yearly ROA, ROE, ROICCURI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

CURI's Gross Margin of 50.40% is in line compared to the rest of the industry. CURI outperforms 54.93% of its industry peers.
In the last couple of years the Gross Margin of CURI has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CURI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
CURI Yearly Profit, Operating, Gross MarginsCURI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

CURI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CURI has more shares outstanding
Compared to 5 years ago, CURI has more shares outstanding
There is no outstanding debt for CURI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CURI Yearly Shares OutstandingCURI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CURI Yearly Total Debt VS Total AssetsCURI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CURI has an Altman-Z score of 3.43. This indicates that CURI is financially healthy and has little risk of bankruptcy at the moment.
CURI's Altman-Z score of 3.43 is amongst the best of the industry. CURI outperforms 80.28% of its industry peers.
CURI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.43
ROIC/WACCN/A
WACC9.32%
CURI Yearly LT Debt VS Equity VS FCFCURI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

CURI has a Current Ratio of 1.66. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CURI (1.66) is better than 73.24% of its industry peers.
CURI has a Quick Ratio of 1.66. This is a normal value and indicates that CURI is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.66, CURI is doing good in the industry, outperforming 76.06% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.66
CURI Yearly Current Assets VS Current LiabilitesCURI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.91% over the past year.
Looking at the last year, CURI shows a very negative growth in Revenue. The Revenue has decreased by -10.12% in the last year.
The Revenue for CURI have been decreasing by -10.47% on average. This is quite bad
EPS 1Y (TTM)83.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.11%
Revenue 1Y (TTM)-10.12%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%25.74%

3.2 Future

Based on estimates for the next years, CURI will show a very strong growth in Earnings Per Share. The EPS will grow by 50.40% on average per year.
CURI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 13.02% yearly.
EPS Next Y72.37%
EPS Next 2Y39.15%
EPS Next 3Y35.9%
EPS Next 5Y50.4%
Revenue Next Year24.71%
Revenue Next 2Y18.63%
Revenue Next 3Y16.5%
Revenue Next 5Y13.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CURI Yearly Revenue VS EstimatesCURI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
CURI Yearly EPS VS EstimatesCURI Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CURI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CURI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CURI Price Earnings VS Forward Price EarningsCURI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200 -300 -400

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as CURI.
The rest of the industry has a similar Price/Free Cash Flow ratio as CURI.
Industry RankSector Rank
P/FCF 47.09
EV/EBITDA 51.63
CURI Per share dataCURI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CURI's earnings are expected to grow with 35.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.15%
EPS Next 3Y35.9%

More info and screens

4

5. Dividend

5.1 Amount

CURI has a Yearly Dividend Yield of 5.10%, which is a nice return.
CURI's Dividend Yield is rather good when compared to the industry average which is at 6.60. CURI pays more dividend than 94.37% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, CURI pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.1%

5.2 History

CURI does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
CURI Yearly Dividends per shareCURI Yearly Dividends per shareYearly Dividends per share 2024 2025 0.05 0.1 0.15 0.2

5.3 Sustainability

CURI has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-31.4%
EPS Next 2Y39.15%
EPS Next 3Y35.9%
CURI Yearly Income VS Free CF VS DividendCURI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

More info and screens

CURIOSITYSTREAM INC

NASDAQ:CURI (5/28/2025, 8:00:00 PM)

Premarket: 6.84 +0.18 (+2.7%)

6.66

+0.12 (+1.83%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryEntertainment
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners9.39%
Inst Owner Change39.59%
Ins Owners6.48%
Ins Owner Change2.19%
Market Cap383.82M
Analysts82.22
Price Target3.03 (-54.5%)
Short Float %1.15%
Short Ratio0.66
Dividend
Industry RankSector Rank
Dividend Yield 5.1%
Yearly Dividend0.07
Dividend Growth(5Y)N/A
DP-31.4%
Div Incr Years0
Div Non Decr Years0
Ex-Date06-13 2025-06-13 (0.1)
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-80.14%
Min EPS beat(2)-83.8%
Max EPS beat(2)-76.49%
EPS beat(4)1
Avg EPS beat(4)-44.66%
Min EPS beat(4)-83.8%
Max EPS beat(4)28.7%
EPS beat(8)2
Avg EPS beat(8)-44.65%
EPS beat(12)5
Avg EPS beat(12)-34.56%
EPS beat(16)8
Avg EPS beat(16)-19.26%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-9.67%
Max Revenue beat(2)3.85%
Revenue beat(4)1
Avg Revenue beat(4)-2.51%
Min Revenue beat(4)-9.67%
Max Revenue beat(4)3.85%
Revenue beat(8)4
Avg Revenue beat(8)-0.8%
Revenue beat(12)6
Avg Revenue beat(12)-3.76%
Revenue beat(16)7
Avg Revenue beat(16)-3.82%
PT rev (1m)8.18%
PT rev (3m)8.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.13%
EPS NY rev (1m)30.35%
EPS NY rev (3m)7.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)11.32%
Revenue NY rev (1m)9.43%
Revenue NY rev (3m)14.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.51
P/FCF 47.09
P/OCF 47.09
P/B 6.63
P/tB 14.57
EV/EBITDA 51.63
EPS(TTM)-0.14
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)0.14
FCFY2.12%
OCF(TTM)0.14
OCFY2.12%
SpS0.89
BVpS1
TBVpS0.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -15.02%
ROE -22.37%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.4%
FCFM 15.94%
ROA(3y)-32.15%
ROA(5y)-36.84%
ROE(3y)-44.33%
ROE(5y)-58.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.26%
GM growth 5YN/A
F-Score7
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion 128.5%
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.66
Altman-Z 3.43
F-Score7
WACC9.32%
ROIC/WACCN/A
Cap/Depr(3y)0.12%
Cap/Depr(5y)1.04%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.11%
EPS Next Y72.37%
EPS Next 2Y39.15%
EPS Next 3Y35.9%
EPS Next 5Y50.4%
Revenue 1Y (TTM)-10.12%
Revenue growth 3Y-10.47%
Revenue growth 5YN/A
Sales Q2Q%25.74%
Revenue Next Year24.71%
Revenue Next 2Y18.63%
Revenue Next 3Y16.5%
Revenue Next 5Y13.02%
EBIT growth 1Y46.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.33%
EBIT Next 3Y51.16%
EBIT Next 5Y26.01%
FCF growth 1Y150.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y150.4%
OCF growth 3YN/A
OCF growth 5YN/A